The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.65 billion ...
Nxera Pharma has sold the Asia-Pacific rights to Idorsia's phase 3-stage autoimmune drug to Viatris for $10 million upfront.
Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral ...
When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in ...
The Department of Health and Human Services is re-evaluating a $590 million contract for avian influenza mRNA vaccines that ...
Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...
Teleflex has announced a plan to split its business into two separate independent companies—and it’s setting up one of its ...
Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in ...
Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...
Clinical trial matchmaker myTomorrows has struck up a partnership with personal health recordkeeper Patients Know Best (PKB) ...
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...
AV0328, one of Alopexx’s lead candidates, is a synthetic PNAG vaccine that has completed a phase 1 trial. The biotech is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results